Home · Solutions · Psychedelics and Novel CNS

Psychedelic and Novel CNS Drug Development

Formulation Development and Clinical Manufacturing for Psychedelic and Novel CNS Drug Products

Psychedelic Drug Development

Occupational Exposure Bands

Our capabilities extend to projects requiring containment up to OEB 5, subject to the specific requirements and assessment of each individual project.

OEB 5

Highly potent / toxic

OEB 4

Potent / toxic

OEB 3

Intermediate potency / toxicity

OEB 2

Low potency / toxicity

OEB 1

Very low potency / toxicity

Supporting the Next Generation of CNS Therapies

The central nervous system (CNS) drug development landscape is evolving rapidly, with growing investment in psychedelic compounds and novel therapeutics targeting a range of neurological and psychiatric conditions. As these programmes advance through development, sponsors require experienced partners capable of navigating complex formulation challenges, regulatory requirements and specialised manufacturing considerations.

At Upperton, we support the development and manufacture of drug products containing psychedelic compounds and novel CNS-active molecules. Combining formulation expertise with integrated analytical and manufacturing capabilities, we help pharmaceutical and biotechnology companies progress innovative therapies from early development through to clinical supply.

Whether your programme involves oral solid dosage forms, nasal delivery, pulmonary products or other specialist formulations, our scientific teams work collaboratively to develop robust drug products that support clinical success.

Psychedelic Drug Development

Supporting Psychedelic Drug Development

As interest in psychedelic-based therapies continues to grow, drug developers require partners with the capability to support clinical development programmes efficiently and compliantly.

Upperton supports the development and manufacture of drug products containing psychedelic compounds, helping clients navigate the challenges associated with bringing these innovative therapies into clinical studies. Through integrated development, analytical and manufacturing services, we provide a streamlined pathway from formulation concept through to clinical supply.